Intermittent fasting-induced amelioration of thyroid hormone sensitivity was associated with improvements in insulin sensitivity independent of weight loss in steatotic liver disease

Abstract

Aim: This study aimed to evaluate the effect of the intermittent fasting (IF) intervention on metabolism and thyroid hormone sensitivity (THS) in patients with steatotic liver disease (SLD) and to further investigate the association between changes in THS and alterations in metabolic parameters during the intervention.

Methods: A total of 78 patients with SLD underwent a 5:2 IF intervention for 8 weeks. Metabolic outcomes and THS, measured by the thyroid feedback quantile-based index (TFQI), thyrotroph thyroxine resistance index, thyroid-stimulating hormone index (TSHI), and free triiodothyronine to free thyroxine ratio (FT3/FT4), were assessed at baseline and after the intervention. Multiple regression analysis was performed to examine relationships between changes in THS and metabolic parameters during the intervention.

Results: Average hepatic fat content was 15.02% at baseline and decreased by 3.79% after the 8-week IF intervention, accompanied by significant reductions in body weight, blood glucose, serum lipids, fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR), and adipose tissue insulin resistance index (Adipo-IR). After the intervention, THS improved: TFQI, thyrotroph thyroxine resistance index, and TSHI all decreased, while FT3/FT4 increased. Significant positive correlations were observed between ΔTFQI and ΔTSHI and changes in fasting insulin, HOMA-IR, and Adipo-IR. In multivariate models adjusted for age, sex, and weight loss, ΔTFQI and ΔTSHI remained significantly correlated with Δinsulin, ΔHOMA-IR, and ΔAdipo-IR.

Conclusion: IF-induced improvement in THS was associated with enhanced insulin sensitivity independent of weight loss in patients with SLD. These findings suggest that THS may play a role in metabolic improvements and could inform therapeutic strategies for SLD.

Keywords

Steatotic liver disease / 5:2 intermittent fasting / thyroid hormone sensitivity / insulin sensitivity / weight loss

References

[1] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol2020;73:202-9

[2] Chen YL,Wu J.Impact of thyroid function on the prevalence and mortality of metabolic dysfunction-associated fatty liver disease.J Clin Endocrinol Metab2023;108:e434-43

[3] Almomani A,Kumar P.Prevalence of hypothyroidism and effect of thyroid hormone replacement therapy in patients with non-alcoholic fatty liver disease: a population-based study.World J Hepatol2022;14:551-8 PMCID:PMC9055192

[4] D’Ambrosio R,Maggioni M.The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD).PLoS One2021;16:e0249614 PMCID:PMC8023543

[5] Laclaustra M,Lou-Bonafonte JM.Impaired sensitivity to thyroid hormones is associated with diabetes and metabolic syndrome.Diabetes Care2019;42:303-10

[6] Zhou L,Su J,Liu J.Vitamin D deficiency is associated with impaired sensitivity to thyroid hormones in euthyroid adults.Nutrients2023;15:3697 PMCID:PMC10490158

[7] Zhang X,Ye H.Correlation between thyroid function, sensitivity to thyroid hormones and metabolic dysfunction-associated fatty liver disease in euthyroid subjects with newly diagnosed type 2 diabetes.Endocrine2023;80:366-79

[8] Wan H,Xu S.Central sensitivity to free triiodothyronine with MAFLD and its progression to liver fibrosis in euthyroid adults.J Clin Endocrinol Metab2023;108:e687-97

[9] de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease.N Engl J Med2019;381:2541-51

[10] Patikorn C,Veettil SK.Intermittent fasting and obesity-related health outcomes: an umbrella review of meta-analyses of randomized clinical trials.JAMA Netw Open2021;4:e2139558 PMCID:PMC8683964

[11] Sutton EF,Early KS,Ravussin E.Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes.Cell Metab2018;27:1212-21.e3 PMCID:PMC5990470

[12] Trepanowski JF,Barnosky A.Effect of alternate-day fasting on weight loss, weight maintenance, and cardioprotection among metabolically healthy obese adults: a randomized clinical trial.JAMA Intern Med2017;177:930-8 PMCID:PMC5680777

[13] Cienfuegos S,Kalam F.Effects of 4- and 6-h time-restricted feeding on weight and cardiometabolic health: a randomized controlled trial in adults with obesity.Cell Metab2020;32:366-78.e3 PMCID:PMC9407646

[14] Harvie M,Pegington M.The effect of intermittent energy and carbohydrate restriction v. daily energy restriction on weight loss and metabolic disease risk markers in overweight women.Br J Nutr2013;110:1534-47 PMCID:PMC5857384

[15] Brunt EM.Nonalcoholic steatohepatitis: definition and pathology.Semin Liver Dis2001;21:3-16

[16] Jospe MR,Brown RC.Intermittent fasting, Paleolithic, or Mediterranean diets in the real world: exploratory secondary analyses of a weight-loss trial that included choice of diet and exercise.Am J Clin Nutr2020;111:503-14

[17] Dorling JL,Redman LM.Calorie restriction for enhanced longevity: the role of novel dietary strategies in the present obesogenic environment.Ageing Res Rev2020;64:101038 PMCID:PMC9036399

[18] Li X,Jia Y.Liraglutide decreases liver fat content and serum fibroblast growth factor 21 levels in newly diagnosed overweight patients with type 2 diabetes and nonalcoholic fatty liver disease.J Diabetes Res2021;2021:3715026 PMCID:PMC8519721

[19] Abu Dayyeh BK, Bazerbachi F, Vargas EJ, et al; MERIT Study Group. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial.Lancet2022;400:441-51

[20] Lv F,Li Y.Sensitivity to thyroid hormone and risk of components of metabolic syndrome in a Chinese euthyroid population.J Diabetes2023;15:900-10 PMCID:PMC10590679

[21] Lai S,Wang Z,Guan H.Sensitivity to thyroid hormone indices are closely associated with NAFLD.Front Endocrinol2021;12:766419 PMCID:PMC8602917

[22] Liu H,Nie Q,Meng C.Association between sensitivity to thyroid hormones and metabolic dysfunction-associated fatty liver disease in euthyroid subjects: a cross-sectional study.Diabetes Metab Syndr Obes2023;16:2153-63 PMCID:PMC10363669

[23] Li R,Chen C.Sensitivity to thyroid hormones is associated with advanced fibrosis in euthyroid patients with non-alcoholic fatty liver disease: a cross-sectional study.Dig Liver Dis2023;55:254-61

[24] Holmer M,Petersson S.Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial.JHEP Rep2021;3:100256 PMCID:PMC8059083

[25] Kord Varkaneh H,Găman MA.Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: a randomized controlled trial.Front Nutr2022;9:948655 PMCID:PMC9360602

[26] Gallage S,Barragan Avila JE.A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1.Cell Metab2024;36:1371-93.e7

[27] Boelen A,Fliers E.Fasting-induced changes in the hypothalamus-pituitary-thyroid axis.Thyroid2008;18:123-9

[28] Moro T,Bianco A.Effects of eight weeks of time-restricted feeding (16/8) on basal metabolism, maximal strength, body composition, inflammation, and cardiovascular risk factors in resistance-trained males.J Transl Med2016;14:290 PMCID:PMC5064803

[29] García-Luna C,Soberanes-Chávez P.Effects of intermittent fasting on hypothalamus-pituitary-thyroid axis, palatable food intake, and body weight in stressed rats.Nutrients2023;15:1164 PMCID:PMC10005667

[30] Domingues-Hajj PMS,Magalhães PKR.Assessment of cardiometabolic risk factors and insulin sensitivity by hyperinsulinemic-euglycemic clamp in resistance to thyroid hormone β syndrome.Thyroid2024;34:1038-46

[31] Wei Y,Cui R,Wang G.Associations between sensitivity to thyroid hormones and insulin resistance in euthyroid adults with obesity.Front Endocrinol2024;15:1366830 PMCID:PMC11338882

[32] Brenta G.Why can insulin resistance be a natural consequence of thyroid dysfunction?.J Thyroid Res2011;2011:152850 PMCID:PMC3175696

[33] Harrison SA,Guy CD.Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.Lancet2019;394:2012-24

[34] Bianco AC.Deiodinases: implications of the local control of thyroid hormone action.J Clin Invest2006;116:2571-9 PMCID:PMC1578599

[35] Ahima RS,Mantzoros C.Role of leptin in the neuroendocrine response to fasting.Nature1996;382:250-2

[36] Mullur R,Brent GA.Thyroid hormone regulation of metabolism.Physiol Rev2014;94:355-82 PMCID:PMC4044302

[37] Vilar-Gomez E,Calzadilla-Bertot L.Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis.Gastroenterology2015;149:367-78.e5; quiz e14

[38] Salas-Salvadó J,Estruch R.Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial.Ann Intern Med2014;160:1-10

[39] Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.Ann Intern Med2010;152:726-32

[40] Patterson RE,LaCroix AZ.Intermittent fasting and human metabolic health.J Acad Nutr Diet2015;115:1203-12 PMCID:PMC4516560

[41] Caussy C,Sirlin CB.Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials.Hepatology2018;68:763-72 PMCID:PMC6054824

[42] Althubaiti A.Information bias in health research: definition, pitfalls, and adjustment methods.J Multidiscip Healthc2016;9:211-7 PMCID:PMC4862344

[43] Fliers E,Kalsbeek A.Novel neural pathways for metabolic effects of thyroid hormone.Trends Endocrinol Metab2010;21:230-6

[44] Grimes DA.Bias and causal associations in observational research.Lancet2002;359:248-52

[45] Zhang Z,Wong VW.Intermittent fasting and metabolic dysfunction-associated steatotic liver disease: the potential role of the gut-liver axis.Cell Biosci2025;15:64 PMCID:PMC12102857